PRA Health Sciences (PRAH) Tops Q1 EPS by 4c, Revenues Beat; Offers 2Q EPS Below Consensus, 2Q Revs. Above Views, Withdraws FY20 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
Go back to PRA Health Sciences (PRAH) Tops Q1 EPS by 4c, Revenues Beat; Offers 2Q EPS Below Consensus, 2Q Revs. Above Views, Withdraws FY20 Outlook
April 28, 2020 6:06 AM EDT
UBS lowered its price target on PRA Health Sciences (NASDAQ: PRAH) to $103.00 (from $116.00) while maintaining a Neutral rating.... More